

Section 1. Identifying Inform	nation		
1. Given Name (First Name) Abby	2. Surname (Last Name) Rosenberg		3. Date 29-January-2019
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Na Shadmehr Demehri	ame 🥊
5. Manuscript Title Skin Cancer Precursor Immunotherapy	for Squamous Cell Carcino	oma Prevention	
6. Manuscript Identifying Number (if you kr 125476-INS-CMED-RV-3	now it)		
1		- 	
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution at any time recein any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere) but not limited to grants, da	ta monitoring board, study de	esign, manuscript preparation,
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	bed in the instructions. Us port relationships that were	e one line for each entity; a	add as many lines as you need by
Section 4. Intellectual Proper	ty Patents & Copyrig	hts	
Do you have any patents, whether plann			Yes ✔No



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Sa	100	-	E
96	CU.	on	0.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Rosenberg has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Mary	2. Surname (Last Name) Tabacchi	3. Date 29-January-2019
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Shadmehr Demehri
5. Manuscript Title Skin Cancer Precursor Immunotherapy	for Squamous Cell Carcino	ma Prevention
6. Manuscript Identifying Number (if you kr 125476-INS-CMED-RV-3	now it)	
Section 2. The Work Under Co	onsideration for Public	ation
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, dat	a third party (government, commercial, private foundation, etc.) for a monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the su	ubmitted work.
of compensation) with entities as descri	bed in the instructions. Use	ther you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .
Are there any relevant conflicts of intere	st? 🗌 Yes 🖌 No	
Section 4. Intellectual Propert	ty Patents & Copyrigl	hte
Do you have any patents, whether plann		



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Tabacchi has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Kenneth	2. Surname (Last Name) Ngo	3. Date 29-January-2019
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Shadmehr Demehri
5. Manuscript Title Skin Cancer Precursor Immunotherapy	for Squamous Cell Carcino	ma Prevention
6. Manuscript Identifying Number (if you kr 125476-INS-CMED-RV-3	now it)	
Section 2. The Work Under Co	onsideration for Public	ation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, dat	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descri	bed in the instructions. Use port relationships that were	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .
Section 4. Intellectual Proper	ty Patents & Copyrig	hts
Do you have any patents, whether planr	ned, pending or issued, bro	adly relevant to the work? Yes 🗸 No



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Ngo has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Michael	2. Surname (Last Name) Wallendorf		3. Date 29-January-2019
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Na Shadmehr Demehri	me
5. Manuscript Title Skin Cancer Precursor Immunotherapy	for Squamous Cell Carcino	oma Prevention	
6. Manuscript Identifying Number (if you ki 125476-INS-CMED-RV-3	now it)		
Section 2. The Work Under C	onsideration for Public	cation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	g but not limited to grants, da	ta monitoring board, study de	sign, manuscript preparation,
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	ibed in the instructions. Us port relationships that wer	e one line for each entity; a	dd as many lines as you need by
Section 4. Intellectual Proper	rty Patents & Copyrig	jhts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work?	Yes 🖌 No
	a X		



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Wallendorf has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Ilana	2. Surname (Last Name) Rosman	3. Date 29-January-2019
4. Are you the corresponding author?	Yes No	Corres <mark>ponding Author's Name</mark> Shadmehr Demehri
5. Manuscript Title Skin Cancer Precursor Immunotherapy	for Squamous Cell Carcinc	oma Prevention
6. Manuscript Identifying Number (if you kr 125476-INS-CMED-RV-3	now it)	
Section 2. The Work Harden		
Section 2. The Work Under Co	onsideration for Public	ation
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere) but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	ubmitted work.
Place a check in the appropriate boxes i of compensation) with entities as descri	n the table to indicate whe bed in the instructions. Us port relationships that were	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .
Section 4. Intellectual Proper	ty Patents & Copyrig	hts
Do you have any patents, whether planr		



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Rosman has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Lynn	2. Surname (Last Name) Cornelius	3. Date 29-January-2019
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Name Shadmehr Demehri
5. Manuscript Title Skin Cancer Precursor Immunotherapy	for Squamous Cell Carcino	oma Prevention
6. Manuscript Identifying Number (if you kn 125476-INS-CMED-RV-3	ow it)	_
Section 2. The Work Under Co		
The work onder Co	onsideration for Public	cation a third party (government, commercial, private foundation, etc.) for
any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, da	ita monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere	st? 🗌 Yes 🖌 No	
Section 3. Relevant financial a	activities outside the s	ubmitted work.
Place a check in the appropriate boxes in of compensation) with entities as described	n the table to indicate who	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by
clicking the "Add +" box. You should rep Are there any relevant conflicts of intere.	ort relationships that wer	e present during the 36 months prior to publication.
Are there any relevant connicts of intere.		
Easting A		
Section 4. Intellectual Propert	ty Patents & Copyrig	hts
Do you have any patents, whether plann If yes, please fill out the appropriate info		oadly relevant to the work? Yes No e more than one entity press the "ADD" button to add a row.
Excess rows can be removed by pressing	the "X" button.	a more main one criticy press the Hob Batton to use a low
Patent? Pendin	g? Issued? Licensed? I	Royalties? Licensee? Comments
PCT/US2015/049434		co-inventor on a filed patent for the use of calcipotriol plus
		5-fluorouracil for the treatment of precancerous skin lesions



Section 5.

Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Cornelius reports In addition, Dr. Cornelius has a patent PCT/US2015/049434 pending.

Evaluation and Feedback



Section 1. Identifying Info	rmation	
1. Given Name (First Name) Shadmehr	2. Surname (Last Name) Demehri	3. Date 29-January-2019
4. Are you the corresponding author?	✓ Yes No	
5. Manuscript Title Skin Cancer Precursor Immunothera	by for Squamous Cell Carcinoma Prevention	
6. Manuscript Identifying Number (if you 125476-INS-CMED-RV-3	ı know it)	
Section 2. The Work Under	Consideration for Publication	
Did you or your institution at any time re	ceive payment or services from a third party (government, ing but not limited to grants, data monitoring board, study	commercial, private foundation, etc.) for design, manuscript preparation,
Section 3. Relevant financi	al activities outside the submitted work.	
of compensation) with entities as des	es in the table to indicate whether you have financial cribed in the instructions. Use one line for each entity report relationships that were present during the 30 erest? Yes No	y; add as many lines as you need by
Section 4. Intellectual Prop	erty Patents & Copyrights	
Do you have any patents, whether pla	anned, pending or issued, broadly relevant to the wo nformation below. If you have more than one entity p	
Patent? Pen	ding? Issued? Licensed? Royalties? Licensee?	Comments
PCT/US2015/049434		co-inventor on a filed patent for the use of calcipotriol plus 5-fluorouracil for the treatment of precancerous skin lesions



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Demehri reports In addition, Dr. Demehri has a patent PCT/US2015/049434 pending.

Evaluation and Feedback

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of
		participants. Describe methods of follow-up
		(b) For matched studies, give matching criteria and number of exposed and
		unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is
		more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) If applicable, explain how loss to follow-up was addressed
		(<i>e</i>) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially
		eligible, examined for eligibility, confirmed eligible, included in the study,
		completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and
		information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
		their precision (eg, 95% confidence interval). Make clear which confounders were
		adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a
		meaningful time period

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and
		sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
		multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if
		applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.